Proteins

Kallikrein 5-IN-2 (compound 21) is a selective Kallikrein KLK5 inhibitor (pIC50=7.1).

MMP-9-IN-6 (Compound 3g) is a MMP-9 inhibitor with IC50 value of 50 μM, which has good anti-ulcer effect.

PFKFB3-IN-2 is a 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase 3 (PFKFB3) inhibitor.

Plasma kallikrein-IN-4 (Example 153) is a plasma kallikrein inhibitor with an IC50 of 0.016 μM against human plasma kallikrein.

MMP-7-IN-2 (compound 16) is a selective inhibitor of MMP7 with an IC50 value of 16 nM.

Aderamastat (FP-025) is an orally active matrix metalloproteinase 12 (MMP-12) inhibitor.

ALP/Carbonic anhydrase-IN-1 (Compound 1e) is a dual carbonic anhydrase (CA) and alkaline phosphatase (ALP) inhibitor.

Elastase is a biochemical reagent that can be used as a biological material or organic compound for life science related research.

Lysyl endopeptidase, Achromobacter sp (Lys-C) catalyzes carboxyl oxygen exchange reaction.

Mca-PLAQAV-Dpa-RSSSR-NH2 is a fluorescent peptide and as one of fluorescent substrates of TNF-α converting enzyme (TACE); ADAM17, ADAM 9 and ADAM 10.

Hepcidin-1 (mouse) TFA is an endogenous peptide hormone involved in the regulation of iron homeostasis.

Lanadelumab (SHP643) is a human IgG1 monoclonal antibody against plasma kallikrein (pKal) with an Ki value of 0.12 nM.

Otelixizumab (ChAglyCD3) is an anti-human CD3 monoclonal antibody and can be used for the research of type 1 diabetes.

Pavurutamab (AMG-701) is a bispecific T cell engager molecule that anti-CD3 and anti-B cell maturation antigens (BCMA).

Ecallantide (DX-88) TFA is a specific recombinant plasma kallikrein inhibitor.

BN-82685 is a a quinone-based CDC25 inhibitor with IC50 of 201 nM, 117 nM, 109 nM, 160 nM, 249 nM, for CDC25C, CDC25C-cat, CDC25A, CDC25B2, CDC25B3, respectively.

1E7-03, a low MW tetradroquinoline derivative targeting protein phosphatase-1, can inhibit HIV-1 transcription.

ND-322 drochloride is a potent and selective water-soluble gelatinase inhibitor.

INCB3619 is a selective and orally active ADAM inhibitor with IC50 of 22 nM and 14 nM for ADAM10 and ADAM17, respectively.

EBNA1-IN-SC7 (compound SC7) is a selective Epstein-Barr nuclear antigen 1 (EBNA1) inhibitor that interferes with EBNA1-DNA binding activity with an IC50 value of 23 μM.

Polatuzumab vedotin is an antibody-drug conjugate targeting CD79b.

Mirvetuximab soravtansine (IMGN853) solution is an anti-folate receptor α (FRα) ADC consisting of the cytotoxic maytansinoid, DM4, covalently linked to the humanized monoclonal antibody M9346A.

Depatuxizumab mafodotin is an antibody-drug conjugate (ADC) that specifically targets the epidermal growth factor receptor (EGFR).

M5N36 is a potent and selective Cdc25C inhibitor with IC50 values of 0.15, 0.19, 0.06 µM for Cdc25A, Cdc25B, Cdc25C, respectively.